Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine in New York and GHESKIO Centers in Haiti.
Researchers in a study published in The Lancet Microbe examined how various tuberculosis treatment regimens affect the respiratory microbiome. They found that certain treatments control tuberculosis effectively while minimally impacting the diversity and health of the respiratory microbiome.
The first clinical trial of a three-month tuberculosis (TB) treatment regimen is closing enrollment because of a high rate of unfavorable outcomes with the investigational course of treatment.